Non-Hodgkin Lymphoma Trial Results
- Rituximab Retreatment after Disease Progression Is Comparable to Rituximab Maintenance Therapy in Patients with Low-Tumor Burden Follicular Lymphoma
(Posted: 10/02/2014) - In a randomized clinical trial, patients with low–tumor burden follicular lymphoma whose cancer responded to initial treatment with rituximab (Rituxan®) experienced similar disease control regardless of whether they subsequently received maintenance therapy with rituximab or were retreated with rituximab only when there was evidence of disease progression.
- NIH trial shows promising results in treating a lymphoma in young people
(Posted: 04/10/2013) - Patients with a type of cancer known as primary mediastinal B-cell lymphoma who received infusions of chemotherapy, but who did not have radiation therapy to an area of the thorax known as the mediastinum, had excellent outcomes, according to clinical trial results.
- Study Suggests New Treatment Option for Some Lymphomas
(Posted: 06/13/2012) - Updated findings from a large European clinical trial indicate that patients with some types of lymphoma could initially be treated with the chemotherapy drug bendamustine (Treanda) and the targeted agent rituximab (Rituxan).
- Romidepsin Reduces Disease Burden and Skin Symptoms in Patients with Previously Treated Cutaneous T-Cell Lymphoma
(Posted: 11/08/2010) - Clinical trial results published October 10, 2010, in The Journal of Clinical Oncology, show that romidepsin (Istodax®), a type of targeted therapy called a histone deacetylase inhibitor, reduced the symptoms and tumor burden of cutaneous T-cell lymphoma in many patients with advanced disease.
- Drug Slows Progression of Cutaneous T-Cell Lymphoma
(Posted: 03/31/2010) - Patients with cutaneous T-cell lymphoma who received the drug denileukin diftitox survived without disease progression for a median of more than 2 years, compared with just over 4 months for patients who received a placebo, according to a study published March 8, 2010, in the Journal of Clinical Oncology.